Market Overview

UPDATE: Swedbank Downgrades AstraZeneca to Sell; Margins Under Pressure

Share:
Related AZN
Jefferies Names AbbVie As Top Pharmaceutical Pick, Offers Alternative Choices
Simons-Founded Renaissance Technologies Buys Apple, Closes Facebook, Trims McDonald's In Q4
Is A Dividend Cut The End Of The World? Total Return And Final Thoughts, Part V (Seeking Alpha)

Swedbank downgraded AstraZeneca (NYSE: AZN) from Reduce to Sell.

Swedbank noted, "Later in March, AstraZeneca will stage its first CMD with a new strategy and a new leadership. It is already clear that this will involve committed investments to transform the pipeline's size and potential. Together with the top-line pressure, this should squeeze the short-term earnings. Upside should be revealed gradually after 2015."

AstraZeneca closed at $45.80 on Thursday.

Latest Ratings for AZN

DateFirmActionFromTo
Feb 2015SEB Equity ResearchUpgradesHoldBuy
Jan 2015Leerink SwannMaintainsMarket Perform
Jan 2015BarclaysDowngradesEqualweightUnderweight

View More Analyst Ratings for AZN
View the Latest Analyst Ratings

Posted-In: SwedbankAnalyst Color Downgrades Analyst Ratings

 

Related Articles (AZN)

Around the Web, We're Loving...

Get Benzinga's Newsletters

Our Experts vs. S&P 500Powered by Benzinga
Marketfy Products Return S&P 500
Morning Profit Maker 42.72% 6.69%
The Option Prophet 91.14% 6.69%
SecretCaps 26.55% 6.69%
Short-Term Trend Trading 11.89% 6.69%
View the highest rated products→